<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Liu S</submitter><funding>Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III)</funding><funding>U.S. Department of Health &amp; Human Services | NIH | National Institute of Mental Health (NIMH)</funding><funding>National Research Foundation of Korea (NRF)</funding><funding>Lundbeckfonden (Lundbeck Foundation)</funding><funding>Norges Forskningsråd (Research Council of Norway)</funding><funding>MOH | National Medical Research Council (NMRC)</funding><funding>Korea Basic Science Institute (KBSI)</funding><funding>Medical Research Council</funding><funding>Department of Health | National Health and Medical Research Council (NHMRC)</funding><funding>Russian Foundation for Basic Research (RFBR)</funding><funding>Japan Agency for Medical Research and Development (AMED)</funding><funding>National Natural Science Foundation of China (National Science Foundation of China)</funding><pagination>1707-1722</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12916477</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>31(3)</volume><pubmed_abstract>Brain network architecture is anticipated to influence future grey matter loss in individuals at Clinical High Risk (CHR) for psychosis. However, existing studies on grey matter structural network properties in CHR are scarce and constrained by small sample sizes. Here, we examined network topology differences comparing a) CHR versus healthy controls (HC); b) CHR who transitioned to psychosis (CHR-T) versus those who did not (CHR-NT); and c) different subsyndromes. We included structural scans from 1842 CHR individuals and 1417 HC individuals from 31 sites within the Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA) consortium. At the global level, CHR individuals exhibited lower structural covariance (q &lt; 0.001; Cohen's d = 0.164) and less optimal structural network configura</pubmed_abstract><journal>Molecular psychiatry</journal><pubmed_title>Structural covariance network topology in individuals at clinical high risk for psychosis: the ENIGMA-CHR Study.</pubmed_title><pmcid>PMC12916477</pmcid><funding_grant_id>INT19/00021</funding_grant_id><funding_grant_id>5T32MH15144 and K23 MH85063</funding_grant_id><funding_grant_id>JP18dm0307001, JP18dm0307004, and JP19dm0207069</funding_grant_id><funding_grant_id>21-BR-03-01</funding_grant_id><funding_grant_id>1196508 and 1150083</funding_grant_id><funding_grant_id>223272</funding_grant_id><funding_grant_id>223273</funding_grant_id><funding_grant_id>PI11/02684 and PI15/00509</funding_grant_id><funding_grant_id>R01MH105246</funding_grant_id><funding_grant_id>1177370 and 1065742</funding_grant_id><funding_grant_id>2020M3E5D9079910</funding_grant_id><funding_grant_id>MR/L011689/1</funding_grant_id><funding_grant_id>566529 and 359223</funding_grant_id><funding_grant_id>1027532, 1137687 and 1027741</funding_grant_id><funding_grant_id>2019R1C1C1002457</funding_grant_id><funding_grant_id>MH076989</funding_grant_id><funding_grant_id>T32MH122394</funding_grant_id><funding_grant_id>K23MH086618 and R01MH081051</funding_grant_id><funding_grant_id>R25-A2701 and R287-2018-1485</funding_grant_id><funding_grant_id>G0700995</funding_grant_id><funding_grant_id>K01MH112774 and R01MH129636</funding_grant_id><funding_grant_id>5R01MH115031</funding_grant_id><funding_grant_id>81871057</funding_grant_id><funding_grant_id>NMRC/TCR/003/2008</funding_grant_id><funding_grant_id>20-013-00748</funding_grant_id><pubmed_authors>Ebdrup BH</pubmed_authors><pubmed_authors>Sorensen ME</pubmed_authors><pubmed_authors>Kaess M</pubmed_authors><pubmed_authors>Mathalon DH</pubmed_authors><pubmed_authors>Pariente JC</pubmed_authors><pubmed_authors>Jalbrzikowski M</pubmed_authors><pubmed_authors>Rasser PE</pubmed_authors><pubmed_authors>Hegelstad WTV</pubmed_authors><pubmed_authors>Schiffman J</pubmed_authors><pubmed_authors>Wenneberg C</pubmed_authors><pubmed_authors>Bachman P</pubmed_authors><pubmed_authors>Koike S</pubmed_authors><pubmed_authors>Waltz JA</pubmed_authors><pubmed_authors>Leon-Ortiz P</pubmed_authors><pubmed_authors>Yuan L</pubmed_authors><pubmed_authors>Westlye LT</pubmed_authors><pubmed_authors>Lin A</pubmed_authors><pubmed_authors>He Y</pubmed_authors><pubmed_authors>Mora-Duran R</pubmed_authors><pubmed_authors>Baldwin H</pubmed_authors><pubmed_authors>Pantelis C</pubmed_authors><pubmed_authors>Dolz M</pubmed_authors><pubmed_authors>Velakoulis D</pubmed_authors><pubmed_authors>Hamilton HK</pubmed_authors><pubmed_authors>Raghava JM</pubmed_authors><pubmed_authors>Cropley VL</pubmed_authors><pubmed_authors>Haas SS</pubmed_authors><pubmed_authors>Lee J</pubmed_authors><pubmed_authors>Sasabayashi D</pubmed_authors><pubmed_authors>Kim M</pubmed_authors><pubmed_authors>Kristensen TD</pubmed_authors><pubmed_authors>Lemmers-Jansen IL</pubmed_authors><pubmed_authors>Resch F</pubmed_authors><pubmed_authors>Tang J</pubmed_authors><pubmed_authors>Værnes TG</pubmed_authors><pubmed_authors>Hooker CI</pubmed_authors><pubmed_authors>Yamasue H</pubmed_authors><pubmed_authors>van Amelsvoort TA</pubmed_authors><pubmed_authors>Vinogradov S</pubmed_authors><pubmed_authors>Amminger GP</pubmed_authors><pubmed_authors>Tor J</pubmed_authors><pubmed_authors>Hernaus D</pubmed_authors><pubmed_authors>Agartz I</pubmed_authors><pubmed_authors>Nordholm D</pubmed_authors><pubmed_authors>Cooper RE</pubmed_authors><pubmed_authors>Wood SJ</pubmed_authors><pubmed_authors>Rossberg JI</pubmed_authors><pubmed_authors>Allen P</pubmed_authors><pubmed_authors>Tomyshev AS</pubmed_authors><pubmed_authors>Klaunig MJ</pubmed_authors><pubmed_authors>Reyes-Madrigal F</pubmed_authors><pubmed_authors>Via E</pubmed_authors><pubmed_authors>Schmidt A</pubmed_authors><pubmed_authors>Lawrie SM</pubmed_authors><pubmed_authors>Ouyang L</pubmed_authors><pubmed_authors>de Haan L</pubmed_authors><pubmed_authors>de la Fuente-Sandoval C</pubmed_authors><pubmed_authors>Heekeren K</pubmed_authors><pubmed_authors>Nordentoft M</pubmed_authors><pubmed_authors>Zhou JH</pubmed_authors><pubmed_authors>Schall U</pubmed_authors><pubmed_authors>Andreassen OA</pubmed_authors><pubmed_authors>Colibazzi T</pubmed_authors><pubmed_authors>Catalano S</pubmed_authors><pubmed_authors>Nelson B</pubmed_authors><pubmed_authors>Chen X</pubmed_authors><pubmed_authors>Loewy RL</pubmed_authors><pubmed_authors>Salisbury DF</pubmed_authors><pubmed_authors>Rivera-Chavez LF</pubmed_authors><pubmed_authors>Moller P</pubmed_authors><pubmed_authors>Fortea A</pubmed_authors><pubmed_authors>Theodoridou A</pubmed_authors><pubmed_authors>Michel C</pubmed_authors><pubmed_authors>Tamnes CK</pubmed_authors><pubmed_authors>Hayes RA</pubmed_authors><pubmed_authors>Chee MW</pubmed_authors><pubmed_authors>Thompson PM</pubmed_authors><pubmed_authors>Kwak YB</pubmed_authors><pubmed_authors>McGorry P</pubmed_authors><pubmed_authors>Suzuki M</pubmed_authors><pubmed_authors>Ma X</pubmed_authors><pubmed_authors>Liu S</pubmed_authors><pubmed_authors>Kwon JS</pubmed_authors><pubmed_authors>Choi S</pubmed_authors><pubmed_authors>Fusar-Poli P</pubmed_authors><pubmed_authors>Takahashi T</pubmed_authors><pubmed_authors>Yung AR</pubmed_authors><pubmed_authors>Kindler J</pubmed_authors><pubmed_authors>ENIGMA Clinical High Risk for Psychosis Working Group</pubmed_authors><pubmed_authors>Hwang WJ</pubmed_authors><pubmed_authors>Glenthoj BY</pubmed_authors><pubmed_authors>Mizrahi R</pubmed_authors><pubmed_authors>Mizuno M</pubmed_authors><pubmed_authors>Katagiri N</pubmed_authors><pubmed_authors>Munoz-Samons D</pubmed_authors><pubmed_authors>Uhlhaas PJ</pubmed_authors><pubmed_authors>Baeza I</pubmed_authors><pubmed_authors>Hubl D</pubmed_authors><pubmed_authors>McGuire P</pubmed_authors><pubmed_authors>Haut KM</pubmed_authors><pubmed_authors>Omelchenko MA</pubmed_authors><pubmed_authors>Smigielski L</pubmed_authors><pubmed_authors>Borgwardt S</pubmed_authors><pubmed_authors>Rossler W</pubmed_authors><pubmed_authors>Kasai K</pubmed_authors><pubmed_authors>Nemoto T</pubmed_authors><pubmed_authors>Bartholomeusz CF</pubmed_authors><pubmed_authors>Lebedeva I</pubmed_authors><pubmed_authors>Cho KIK</pubmed_authors><pubmed_authors>Thomopoulos SI</pubmed_authors><pubmed_authors>Horton LE</pubmed_authors><pubmed_authors>Corcoran CM</pubmed_authors><pubmed_authors>Glenthoj LB</pubmed_authors><pubmed_authors>Sugranyes G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Structural covariance network topology in individuals at clinical high risk for psychosis: the ENIGMA-CHR Study.</name><description>Brain network architecture is anticipated to influence future grey matter loss in individuals at Clinical High Risk (CHR) for psychosis. However, existing studies on grey matter structural network properties in CHR are scarce and constrained by small sample sizes. Here, we examined network topology differences comparing a) CHR versus healthy controls (HC); b) CHR who transitioned to psychosis (CHR-T) versus those who did not (CHR-NT); and c) different subsyndromes. We included structural scans from 1842 CHR individuals and 1417 HC individuals from 31 sites within the Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA) consortium. At the global level, CHR individuals exhibited lower structural covariance (q &lt; 0.001; Cohen's d = 0.164) and less optimal structural network configura</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Mar</publication><modification>2026-07-16T09:57:49.547Z</modification><creation>2026-07-09T10:49:40.931Z</creation></dates><accession>S-EPMC12916477</accession><cross_references><pubmed>41125743</pubmed><doi>10.1038/s41380-025-03304-6</doi></cross_references></HashMap>